BioTech Capital throws in the towel
Friday, 13 August, 2010
BioTech Capital One, of the highest profile Australian biotech investment funds announced on Thursday that it will no longer pursue new opportunities in the sector and will liquidate its current investment portfolio, returning the proceeds to shareholders.
The only publicly-listed biotech investment fund in Australia, BTC cited drawbacks associated with “running private equity style mandates”, especially the inability to communicate the group’s diverse range of holdings, in particular its private investments. BTC said that this meant that the stock was constantly under priced. The announcement triggered the retirement of company non-executive director Professor Tony Basten.
BTC said that it would provision $4.6 million in addition to $0.213 per share to accelerate completion of projects still carrying value.
Today’s announcement terminates several years early the arrangement between BTC and its investment manager Titan Bioventures Management. BTC said that it would ask shareholders to approve a move to acquire Titan, thereby bringing its management function in-house.
Anti-inflammatory agent could decrease septic shock mortality
Researchers have discovered a naturally occurring blood protein — a type of...
Less penicillin needed to treat Strep A infection than we thought
It's never been known exactly how much penicillin prevents sore throats — the most...
Stress disrupts emotion control in mental illness
Acute stress may impair key brain functions involved in managing emotions — particularly in...
